(NASDAQ: ALPN) Alpine Immune Sciences's forecast annual revenue growth rate of -9.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Alpine Immune Sciences's revenue in 2024 is $56,521,000.On average, 3 Wall Street analysts forecast ALPN's revenue for 2024 to be $1,531,988,570, with the lowest ALPN revenue forecast at $823,170,324, and the highest ALPN revenue forecast at $2,743,901,080. On average, 2 Wall Street analysts forecast ALPN's revenue for 2025 to be $2,743,901,080, with the lowest ALPN revenue forecast at $2,743,901,080, and the highest ALPN revenue forecast at $2,743,901,080.
In 2026, ALPN is forecast to generate $2,401,599,420 in revenue, with the lowest revenue forecast at $2,401,599,420 and the highest revenue forecast at $2,401,599,420.